Scholarlink

Objectives <p>To evaluate the diagnostic performance of contrast-enhanced mammography (CEM) for detecting residual disease (RD) and assessing residual tumor size after neoadjuvant chemotherapy (NAC) in breast cancer, comparing early-only, delayed-only, and combined acquisition protocols.</p> Materials and methods <p>This retrospective single-center diagnostic performance study included consecutive women with biopsy-proven breast cancer who underwent pre- and post-NAC CEM with both early and delayed acquisitions and subsequent surgery (2016–2024). Patients without complete CEM protocols or surgical pathology were excluded. CEM images were independently analyzed for each protocol by two experienced breast radiologists in consensus. Radiological response was categorized per RECIST and dichotomized as complete response versus RD. Pathological tumor staging (ypT) at surgery was the gold standard; pathologic complete response (pCR) was defined as ypT0/ypTis. Diagnostic performance in predicting RD was calculated for each protocol with sensitivity and negative predictive value (NPV) as primary endpoints (χ² test). Bland–Altman analysis compared imaging-measured and pathological tumor sizes.</p> Results <p>Of 202 women included (mean age, 54.7 ± 12.7), 83 (41.1%) achieved pCR. Sensitivity for detecting RD was higher for delayed (85.7%, 95% CI 78.1–91.5%) and combined protocols (86.6%, 79.1–92.1%) compared to early (68.1%, 58.9–76.3%; <i>p</i> &lt; 0.0001). NPV improved from 58.2% (95% CI 48.3–67.6%) to 71.2% (62.3–79.0%; <i>p</i> = 0.04) with delayed acquisitions. Bland–Altman analysis showed slightly better agreement between early images and pathology (mean difference 5.7 mm) than for delayed acquisitions (11.8 mm).</p> Conclusions <p>Delayed CEM images significantly improved sensitivity and NPV in predicting RD, supporting the inclusion of delayed acquisitions in the neoadjuvant setting.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>Can contrast-enhanced mammography protocols be optimized after neoadjuvant chemotherapy to improve the detection of pathological residual disease and residual tumor size assessment?</i></p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>Delayed contrast-enhanced mammography acquisitions significantly improved sensitivity and negative predictive value for residual disease detection, whereas early acquisitions provided slightly better agreement for residual tumor size.</i></p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>Including delayed images in post-neoadjuvant contrast-enhanced mammography improves detection of residual invasive disease, supporting surgical planning, while early images remain useful for tumor size estimation.</i></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Chiara Bellini,
  • Giulia Bicchierai,
  • Chiara Maiello,
  • Francesco Amato,
  • Diego de Benedetto,
  • Federica di Naro,
  • Sofia Vidali,
  • Paolina Tonelli,
  • Ermanno Vanzi,
  • Cecilia Boeri,
  • Luca Visani,
  • Vania Vezzosi,
  • Lorenzo Orzalesi,
  • Tommaso Susini,
  • Vittorio Miele,
  • Jacopo Nori

摘要

Objectives

To evaluate the diagnostic performance of contrast-enhanced mammography (CEM) for detecting residual disease (RD) and assessing residual tumor size after neoadjuvant chemotherapy (NAC) in breast cancer, comparing early-only, delayed-only, and combined acquisition protocols.

Materials and methods

This retrospective single-center diagnostic performance study included consecutive women with biopsy-proven breast cancer who underwent pre- and post-NAC CEM with both early and delayed acquisitions and subsequent surgery (2016–2024). Patients without complete CEM protocols or surgical pathology were excluded. CEM images were independently analyzed for each protocol by two experienced breast radiologists in consensus. Radiological response was categorized per RECIST and dichotomized as complete response versus RD. Pathological tumor staging (ypT) at surgery was the gold standard; pathologic complete response (pCR) was defined as ypT0/ypTis. Diagnostic performance in predicting RD was calculated for each protocol with sensitivity and negative predictive value (NPV) as primary endpoints (χ² test). Bland–Altman analysis compared imaging-measured and pathological tumor sizes.

Results

Of 202 women included (mean age, 54.7 ± 12.7), 83 (41.1%) achieved pCR. Sensitivity for detecting RD was higher for delayed (85.7%, 95% CI 78.1–91.5%) and combined protocols (86.6%, 79.1–92.1%) compared to early (68.1%, 58.9–76.3%; p < 0.0001). NPV improved from 58.2% (95% CI 48.3–67.6%) to 71.2% (62.3–79.0%; p = 0.04) with delayed acquisitions. Bland–Altman analysis showed slightly better agreement between early images and pathology (mean difference 5.7 mm) than for delayed acquisitions (11.8 mm).

Conclusions

Delayed CEM images significantly improved sensitivity and NPV in predicting RD, supporting the inclusion of delayed acquisitions in the neoadjuvant setting.

Key Points

Question Can contrast-enhanced mammography protocols be optimized after neoadjuvant chemotherapy to improve the detection of pathological residual disease and residual tumor size assessment?

Findings Delayed contrast-enhanced mammography acquisitions significantly improved sensitivity and negative predictive value for residual disease detection, whereas early acquisitions provided slightly better agreement for residual tumor size.

Clinical relevance Including delayed images in post-neoadjuvant contrast-enhanced mammography improves detection of residual invasive disease, supporting surgical planning, while early images remain useful for tumor size estimation.

Graphical Abstract